Current Report · Items 3.03, 5.03, 9.01 · 8-K
Curis, Inc.
CRISNASDAQEQUITYCurrent
Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 3.03. Material Modification to Rights of Security Holders. To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 below is incorporated herein by reference.
Filed Jul 2, 2026Accepted Jul 2, 2026, 8:56 AM EDTCIK 1108205Accession 0001108205-26-000078
Company context
We are a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase, or IRAK4 and FMS-like tyrosine kinase 3 or FLT3. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma, or PCNSL, in combination with ibrutinib, a Bruton Tyrosine Kinase inhibitor or BTK inhibitor and in our recently initiated TakeAim CLL study, a Phase 2 combination study of emavusertib in chronic lymphocytic leukemia, or CLL, with zanubrutinib, a BTK inhibitor. Our monotherapy and combination studies of emavusertib in AML are substantially complete. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration, or FDA, for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. We, through our 2015 collaboration with Aurigene Discovery Technologies Limited, or Aurigene, have the exclusive license to emavusertib (CA-4948).
Current securities
Disclosure sections
Items 3.03, 5.03, 9.01Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 3.03Item 3.03 - Material Modification to Rights
Item 3.03. Material Modification to Rights of Security Holders.
To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 below is incorporated herein by reference.
Item 5.03Item 5.03 - Amendments to Articles/Bylaws
Item 5.03.
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On July 2, 2026, Curis, Inc. (the “Company”) filed a certificate of amendment to the Company’s Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware (“Certificate of Amendment”), which will effect, as of 5:00 p.m. Eastern Time on July 2, 2026 (“Effective Time”) a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding common stock, $0.01 par value per share (“Common Stock”).
As a result of the Reverse Stock Split, every 20 shares of the Company’s issued and outstanding Common Stock will be converted into one share of Common Stock. No fractional shares will be issued, and stockholders who would otherwise be entitled to receive a fractional share of Common Stock as a result of the Reverse Stock Split will have such fractional share of Common Stock rounded up to the nearest whole share.
The Reverse Stock Split will not change the par value of the Common Stock or the number of authorized shares of Common Stock. All outstanding warrants, restricted stock units and stock options will be adjusted as a result of the Reverse Stock Split, as well as the corresponding exercise price, as applicable, as well as the number of shares that remain available for future issuance under the Company’s equity incentive plans, as provided by the terms of such warrants, restricted stock units, stock options and incentive plans and described in the Company’s proxy statement for the Company’s Special Meeting as filed with the Securities and Exchange Commission on June 5, 2026.
Trading of the Company’s common stock on a Reverse Stock Split-adjusted basis will begin at the opening of trading on July 6, 2026. The Common Stock will continue to trade under the existing ticker symbol “CRIS.” The new CUSIP number for the Common Stock following the Reverse Stock Split is 231269408.
The foregoing description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.